Better imaging biomarkers can improve early diagnosis and trial stratification—useful for translational studies—but as an editorial without new mechanistic or therapeutic data its direct value for drug discovery is limited.

This paper outlines scalable, objective behavioral endpoints and multimodal strategies that can improve preclinical screening, biomarker development, and linkage of motor phenotypes to neural activity—accelerating therapeutic evaluation—though it does not provide direct mechanistic targets or…

Demonstrates a feasible, tolerable, and potentially objective VR-based phenotyping approach that could be developed as a biomarker or outcome measure for trials targeting visual hallucinations, though the small sample size and technical limitations limit immediate therapeutic translation.

Standardizing and clarifying voice-acoustic features can improve development and reliability of speech-based biomarkers for Parkinson's disease diagnosis and monitoring, aiding patient stratification and outcome measurement in trials, though it offers little direct insight into therapeutic…

This paper has low direct value for Parkinson's therapeutic discovery but is relevant epidemiologically by flagging environmental water contaminants as possible PD risk factors that could justify targeted exposure studies to inform prevention and mechanistic research.

Offers moderate repurposing potential for Parkinson's by highlighting neuroprotective and symptomatic mechanisms, but the lack of PD‑specific data, absent abstract, and limited coverage of key PD pathways (alpha‑synuclein, mitochondria, lysosomes) reduce its immediate translational value.

The compound's reported anti-inflammatory and antioxidant profiles could be relevant to PD-related pathways (mitochondria, neuroinflammation, proteostasis), making it a candidate for follow-up assays, yet the current article offers low immediate actionability for Parkinson’s therapeutic discovery.

Better CT-guided normalization can improve accuracy and reproducibility of DAT SPECT biomarkers for diagnosis, patient stratification, and monitoring in Parkinson's therapeutic trials, though it does not provide direct mechanistic or interventional insights.

While not offering molecular or therapeutic targets, the paper identifies candidate biomechanical biomarkers and measurement gaps that could inform clinical phenotyping, outcome measures, and rehabilitation strategies relevant to Parkinson's gait dysfunction and trial design.

Brain-age prediction methods can provide noninvasive biomarkers for early diagnosis, disease monitoring, and trial stratification in PD, improving translational research and clinical evaluation despite not directly revealing therapeutic mechanisms.

By linking metabolic/inflammatory mechanisms (and potential repurposing of diabetes drugs) to neurodegeneration, the paper could guide translational strategies for PD, but its narrative format and missing abstract reduce immediate actionability.

By concentrating on peripheral immune pathways and their communication with the CNS (including inflammation and potential gut–brain interactions), it may point to biomarkers and immune-modulating therapeutic strategies, though the missing abstract limits assessment of novelty and actionability.

These genes point to lysosomal dysfunction, a therapeutically actionable pathway and biomarker axis relevant to GBA-related and broader PD biology, but being a correction with no abstract or new experimental data limits immediate translational impact until the original findings are reviewed.

Clinically relevant for optimizing levodopa delivery and reducing motor fluctuations (high translational value), but offers limited mechanistic or disease‑modifying insight and evaluation is constrained by the missing abstract.

Findings are clinically actionable because reduced levodopa-induced homocysteine via COMT inhibition could lower vascular and potential neurotoxic risk and guide adjunct strategies (COMT inhibitor choice or B‑vitamin management) to improve long-term outcomes, though lack of an abstract limits…

Highlights the gut–brain axis and microbiome as promising, translational targets for PD diagnostics and interventions, but absence of an abstract and likely review nature limit immediate actionable insights.

If levodopa contributes to neuropathy via metabolic changes (e.g., B12/homocysteine pathways), the finding could guide monitoring, simple supplementation or management strategies to improve safety and tolerability of a cornerstone therapy, though it is less directly informative about core…

If supported by experimental data, this gut-immune—ENS connection could yield biomarkers or therapeutic entry points to modulate inflammation or block pathology spread, but the missing abstract limits assessment of actionable evidence and translational readiness.

Macrophage-focused research intersects with inflammation, alpha-synuclein clearance, and peripheral biomarkers—areas with translational and therapeutic potential—yet the missing abstract and likely speculative review format limit immediate actionability for drug discovery.

Connects metabolism, homocysteine and methylation to neurodegeneration and highlights biomarker and repurposing opportunities (e.g., folate supplementation), but is non‑specific to Parkinson's and lacks clear, actionable therapeutic targets or novel PD‑focused data.